close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

286.74 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
96 97 Next >
News headline image
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy ↗
Despite its high price relative to earnings, AbbVie remains an attractive stock. 
Via The Motley Fool
News headline image
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk. 
Via MarketBeat
News headline image
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer ↗
They definitely matter... up to a point. 
Via The Motley Fool
Topics Bonds Economy
News headline image
Great News for AbbVie Stock Investors ↗
The company is gearing up for future major patent cliffs. 
Via The Motley Fool
Topics Intellectual Property
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting ↗
Via Chartmill
Topics Cannabis
News headline image
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. ↗
This pharma leader has a history of outperforming during rising interest rates. 
Via The Motley Fool
Topics Bonds Economy
News headline image
2 High-Flying Dividend Stocks to Buy and Hold for a Decade ↗
They may just be getting started. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗
Buffett has warned about "gambling" in the market. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗
It was Griffin's biggest add for Citadel last quarter. 
Via The Motley Fool
Topics Economy
News headline image
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle ↗
Rising rates can expose dividend traps, but this Dividend King is built to keep paying. 
Via The Motley Fool
Topics Credit Cards
News headline image
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys ↗
These funds can help you weather any storm that might be on the way. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends ↗
You'd need to invest over $200,000 in the pharma leader at its current price. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year. 
Via The Motley Fool
Topics Intellectual Property
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq ↗
Via Chartmill
Topics Economy
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium. 
Via The Motley Fool
News headline image
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway. ↗
A super-high yield isn't everything. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb. 
Via The Motley Fool
Topics Intellectual Property
News headline image
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens ↗
These companies might bend during a downturn, but they won’t break. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Energy
News headline image
5 Stocks to Buy That Have Raised Their Dividends Every Year Since 2000 ↗
Each of these stocks, representing a different sector, is on an impressive run of dividend growth. 
Via The Motley Fool
Topics Artificial Intelligence
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
3 of the Best Growth Stocks to Buy in October 2026 ↗
These stocks have tremendous businesses, and their valuations are incredibly low. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. ↗
A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie. 
Via The Motley Fool
News headline image
Should You Buy AbbVie Stock Before Oct. 30? ↗
The healthcare company will release its third-quarter numbers later this month. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
96 97 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.